Vivos Therapeutics, Inc. announced the results of a recent clinical observational study on the application of Vivos' recently acquired Preventive Oral Devic (known as The POD®) in the treatment and prevention of migraine headaches. The study demonstrated statistically significant results, with ninety-two percent (92%) of study patients reporting their migraine symptoms were completely resolved following completion of treatment. Moreover, the results were maintained during follow-up visits extending from 3 to 28 months after treatment began.

Migraine severity was measured by the validated Migraine Disability Assessment Questionnaire (MIDAS). Prior to treatment patients had an average MIDAS score of 23.96 +/- 21.34 and following treatment had a MIDAS score of 2.58 +/- 4.87, a reduction of 89.2%. Migraine headaches affect over 39 million people in the United States alone according to the American Migraine Foundation.

This common debilitating pain condition can impact people for decades, with many choosing to accept living in pain after seeking treatment which proved ineffective. With this new treatment available from Vivos, patients can now find highly effective non-pharmaceutical relief from their local dentist.